(S)-N-(3-(2-amino-4-(difluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide | 1310877-09-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-N-(3-(2-amino-4-(difluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide
• 英文别名: N-{3-[(4s)-2-Amino-4-(Difluoromethyl)-5,6-Dihydro-4h-1,3-Oxazin-4-Yl]-4-Fluorophenyl}-5-Cyanopyridine-2-Carboxamide；N-[3-[(4S)-2-amino-4-(difluoromethyl)-5,6-dihydro-1,3-oxazin-4-yl]-4-fluorophenyl]-5-cyanopyridine-2-carboxamide
• CAS: 1310877-09-8
• 化学式: C₁₈H₁₄F₃N₅O₂
• 分子量: 389.337
• InChiKey: ZQBDXEARYNLKKR-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (S)-4-(5-amino-2-fluorophenyl)-4-(difluoromethyl)-5,6-dihydro-4H-1,3-oxazin-2-amine 、 5-氰基-2-吡啶羧酸 在 4-(4,6-二甲氧基三嗪-2-基)-4-甲基吗啉盐酸盐 、 sodium carbonate 作用下， 以 甲醇 、 水 为溶剂， 反应 16.5h， 以73.2%的产率得到(S)-N-(3-(2-amino-4-(difluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide
  参考文献：
  名称：

  [EN] HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
  [FR] HALOGÉNO-ALKYL-1,3 OXAZINES EN TANT QU'INHIBITEURS DE BACE1 ET/OU BACE2

  摘要：

  本发明提供具有BACE1和/或BACE2抑制活性的式(I)化合物，它们的制备方法，包含它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用于治疗和/或预防例如阿尔茨海默病和2型糖尿病等疾病。

  公开号：

  WO2012168164A1

文献信息

• HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS
  申请人：Siena Biotech S.p.A.

  公开号：US20140080819A1

  公开（公告）日：2014-03-20

  The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明提供具有BACE1和/或BACE2抑制活性的化合物(I)的公式，它们的制备，含有它们的药物组合物以及它们作为治疗活性物质的用途。本发明的活性化合物在治疗和/或预防治疗例如阿尔茨海默病和2型糖尿病方面是有用的。
• Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
  申请人：Woltering Thomas

  公开号：US08987255B2

  公开（公告）日：2015-03-24

  The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

  本发明提供了具有BACE1和/或BACE2抑制活性的式（I）化合物，它们的制造方法，包含它们的制药组合物以及它们作为治疗活性物质的用途。本发明的活性化合物可用于治疗和/或预防例如阿尔茨海默病和2型糖尿病等疾病。
• DIHYDROOXAZINE OR OXAZEPINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：US20150266865A1

  公开（公告）日：2015-09-24

  The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins. A compound of the formula (I): wherein X is —C(R 3a )(R 3b )—, —C(R 3a )(R 3b )—C(R 3c )(R 3d )— or —C(R 3a )═C(R 3c )—, R 1 is substituted or unsubstituted alkyl or the like, R 2a , R 2b , R 3a , R 3b , R 3c and R 3d are each independently hydrogen, halogen or the like, R 4 is hydrogen or halogen, Ring B is substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种化合物，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作治疗或预防由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的药物。化合物的公式（I）如下：其中X为—C（R3a）（R3b）—，—C（R3a）（R3b）C（R3c）（R3d）—或—C（R3a）═C（R3c）—，R1为取代或未取代的烷基或类似物，R2a，R2b，R3a，R3b，R3c和R3d分别独立地为氢、卤素或类似物，R4为氢或卤素，环B为取代或未取代的碳环或取代或未取代的杂环，或其药学上可接受的盐。
• OXAZINE DERIVATIVE
  申请人：Shionogi & Co., Ltd.

  公开号：EP2511268B1

  公开（公告）日：2016-07-13
• OXAZINE DERIVATIVES
  申请人：Shionogi & Co., Ltd.

  公开号：US20150166491A1

  公开（公告）日：2015-06-18

  The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins. A compound of the formula (I): wherein R 1 , R 2a , R 2b , R 3 , R 4a , R 4b , ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.